In the HR-positive population, the survival advantage of HER2-low tumors was more significant among women with ductal adenocarcinoma (p-interaction < 0.01), those who received any chemotherapy (p-interaction = 0.02) (Fig. 4B). Here, ERBB2 is linked to invasive ductal breast carcinoma.